ResearcherNew York UniversityActive in the last 2 years

Daniel Brock Hewitt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6556-3830; OpenAlex author ID A5080682983. Sources: OpenAlex.

Their work

Papers: 24 (first author 0, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 92

Papers, trials and grants by year

2022: 2 papers · 2023: none · 2024: 6 papers · 2025: 13 papers · 2026: 3 papers

Papers 24

Clinical and molecular features of resected early onset pancreatic ductal adenocarcinoma: insights from the NCDB and cBioPortal. Co-author DOI 10.1016/j.hpb.2025.12.026 ↗
Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011 ↗
Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058 ↗
Histotripsy of Pancreatic Cancer Liver Metastases: Early Outcomes and Imaging Findings. Last author DOI 10.1002/wjs.12646 ↗
Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis. Co-author DOI 10.1016/j.ejso.2025.109742 ↗
Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer. Last author DOI 10.1016/j.surg.2024.109114 ↗
Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037 ↗
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196 ↗
Defining the Minimal and Optimal Thresholds for Lymph Node Resection and Examination for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: A M… Co-author DOI 10.1097/sla.0000000000006295 ↗
Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687 ↗
Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735 ↗
Transitional Type Circulating Tumor Cells Predict Systemic Recurrence and Support Risk Stratification for Chemotherapy After Resection of Pancreatic Ductal Ade… Co-author DOI 10.1097/sla.0000000000006998 ↗
Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Co-author DOI 10.1245/s10434-024-16673-z ↗
Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… Co-author DOI 10.1245/s10434-025-17810-y ↗
The Impact of Social Determinants on Pancreatic Cancer Care in the United States. Co-author DOI 10.3390/cancers17121898 ↗
The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Co-author DOI 10.3390/cancers17193254 ↗
The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.06.004 ↗
An international multi-institutional validation of T1 sub-staging of intraductal papillary mucinous neoplasm-derived pancreatic cancer. Co-author DOI 10.1093/jnci/djae166 ↗
Progression of Site-specific Recurrence of Pancreatic Cancer and Implications for Treatment. Co-author DOI 10.1097/sla.0000000000006142 ↗
Outcomes in intraductal papillary mucinous neoplasm-derived pancreatic cancer differ from PanIN-derived pancreatic cancer. Co-author DOI 10.1111/jgh.16686 ↗
Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193 ↗
Deep Learning Applications in Pancreatic Cancer. Last author DOI 10.3390/cancers16020436 ↗
Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Co-author DOI 10.1016/j.suronc.2022.101803 ↗
Comment on: "Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer". Co-author DOI 10.1245/s10434-022-11840-6 ↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.